Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Radiotherapy Clinical Trial

Official title:

The Safety and Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Squamous Cell Carcinoma.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05176002
• Other study ID #: NIRE UNION
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 23, 2021
• Est. completion date: September 2024

Study information

• Verified date: December 2021
• Source: Fujian Medical University Union Hospital
• Contact: Chun Chen, Dortor
• Phone: 15959002753
• Email: lacustrian[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an exploratory phase II clinical study designed to evaluate the safety and efficacy of Camrelizumab in combination with standard radiotherapy as preoperative neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma. In the study, all subjects who met the enrollment criteria are enrolled after giving full informed consent and signing the enrollment informed consent form, and received radical surgery within 4-8 weeks after completion of neoadjuvant Camrelizumab in combination with standard radiotherapy. The safety evaluation indicators for the study were so adverse events and the number and proportion of subjects who discontinued treatment due to adverse events. The main efficacy indicators of the study were the rate of major pathological remission and the rate of complete pathological remission. A total of 26 cases had to be enrolled in the study. Phase I enrollment was 12 cases, with at least 5 cases achieving efficacy to proceed to Phase II. The trial was considered successful when 14 cases were enrolled in the second phase and the total number of effective cases was greater than 13. The need for postoperative adjuvant treatment and the adjuvant treatment plan were determined by the investigator, and all subjects were required to complete the study's follow-up plan after surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 26
• Est. completion date: September 2024
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Signed written informed consent prior to the implementation of any trial-related rocedures;

2. Male or female, =18 years of age or =75 years of age;

3. Patients with a confirmed diagnosis of esophageal squamous cell carcinoma by pathological histology of the primary site biopsy;

4. Patients who are judged to be operable and in need of neoadjuvant therapy by imaging and esophagoscopy ( cT1b-2N+/ cT3-4aN0-3M0), stage II-IVA;

5. The main body of the patient's tumor is located in the mid- and lower thoracic segment of the esophagus as judged by imaging and esophagoscopy (the central location of the tumor is horizontally below the arch of the odd vein, measured endoscopically = 24 cm from the incisors);

6. There is at least one imaging measurable lesion according to the solid tumor efficacy evaluation criteria (RECIST version 1.1);

7. The patient Have not received any prior antitumor therapy, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.;

8. ECOG score 0-1;

9. Adequate organ function, subjects need to meet the following laboratory indices:

1. Absolute neutrophil count (ANC) = 1.5x109/L in the last 14 days without granulocyte colony-stimulating factor ;

2. Platelets = 100 x 109/L in the absence of blood transfusion in the last 14 days;

3. Hemoglobin >9 g/dL without blood transfusion or erythropoietin in the last 14 days;

4. Total bilirubin =1.5 x upper limit of normal (ULN); or total bilirubin >ULN but direct bilirubin = ULN;

5. Portaline aminotransferase (AST), alanine aminotransferase (ALT) at =2.5×ULN;

6. blood creatinine = 1.5 x ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) = 60 ml/min;

7. good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) = 1.5 times ULN;

8. normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may also be enrolled;

9. Myocardial enzyme profile within the normal range (simple laboratory abnormalities that are not clinically significant, as determined by the investigator, are also allowed).

10. For female subjects of childbearing potential, a negative urine or serum pregnancy test should be performed within 3 days prior to the first dose of study drug (Cycle 1, Day 1). If a negative urine pregnancy test result cannot be confirmed, a blood pregnancy test will be requested. Non-reproductive females are defined as being at least 1 year post-menopausal or having undergone surgical sterilization or hysterectomy;

11. If there is a risk of conception, all subjects (male or female) are required to use contraception with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the final study drug dose.

Exclusion Criteria:

1. patients with an untreated diagnosis of another malignancy within 5 years prior to the first dose (excluding radically treated basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or radically resected carcinoma in situ)

2. patients at risk for tracheoesophageal fistula or aortoesophageal fistula

3. currently participating in an interventional clinical study treatment or have received another study drug or been treated with an investigational device within 4 weeks prior to the first dose

4. have received prior therapy with: an anti-PD-1, anti-PD-L1 or anti-PD-L2 drug or a drug targeting another stimulatory or co-suppressive T-cell receptor (e.g., CTLA-4, OX-40, CD137).

5. systemic systemic therapy with a proprietary Chinese medicine or immunomodulatory agent (including thymidine, interferon, interleukin, except for local use to control pleural fluid) with an antitumor indication within 2 weeks prior to the first dose.

6. active autoimmune disease requiring systemic therapy (e.g., with disease-relieving drugs, glucocorticoids, or immunosuppressive agents) that occurred within 2 years prior to the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy.

7. is receiving systemic glucocorticoid therapy (excluding nasal spray, inhaled or other routes of topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study. Note: Physiological doses of glucocorticoids (=10 mg/day of prednisone or equivalent) are permitted.

8. known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation

9. known hypersensitivity to the active ingredient or excipients of the investigational drug Camrelizumab;

10. those with multiple factors affecting oral drug administration (e.g., inability to swallow, post-gastrectomy, chronic diarrhea, and intestinal obstruction)

11. have not recovered sufficiently from toxicity and/or complications from any intervention prior to initiation of therapy (i.e., = grade 1 or at baseline, excluding malaise or alopecia)

12. known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibody) and various viral hepatitis infections

13. live vaccination within 30 days prior to the first dose (Cycle 1, Day 1). Note:

Injectable inactivated viral vaccine for seasonal influenza within 30 days prior to the first dose is permitted; however, intranasal administration of live attenuated influenza vaccine is not permitted.

14. women who are pregnant or breastfeeding.

15. Presence of any serious or uncontrollable systemic disease, such as

1. Resting ECG with significant and severely symptomatic uncontrollable abnormalities in rhythm, conduction or morphology, such as complete left bundle branch block, second degree or greater heart block, ventricular arrhythmia or atrial fibrillation.

2. Unstable angina, congestive heart failure, chronic heart failure of New York Heart Association (NYHA) classification = 2.

3. myocardial infarction within 6 months prior to randomization

4. suboptimal blood pressure control (systolic blood pressure > 140 mmHg and diastolic blood pressure > 90 mmHg)

5. history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to first dose, or current clinically active interstitial lung disease.

6. active pulmonary tuberculosis.

7. the presence of an active or uncontrolled infection requiring systemic therapy

8. presence of clinically active diverticulitis, abdominal abscesses, gastrointestinal obstruction

9. the presence of liver disease such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis

10. poorly controlled diabetes mellitus (fasting blood glucose (FBG) > 10 mmol/L)

11. urine routine suggesting urine protein =++ and confirmed 24-hour urine protein quantification >1.0 g

12. patients with mental disorders and unable to cooperate with treatment

16. have a medical history or evidence of disease that may interfere with the results of the trial, prevent the subject from participating in the study throughout, abnormal treatment or laboratory test values, or other conditions that the investigator considers unsuitable for enrollment The investigator considers that there are other potential risks unsuitable for participation in this study.

Related Conditions & MeSH terms

• Esophageal Neoplasm
• Esophageal Neoplasms
• Immunotherapy
• Radiotherapy

Intervention

Drug:
• Camrelizumab
Neoadjuvant Camrelizumab combined with radiotherapy

Locations

Country	Name	City	State
China	Fujian Medical University Union Hospital	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Medical University Union Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	Major pathological remission rate	2 week after operation
Primary	Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	Number and percentage of cases of all adverse events	2 week after operation
Secondary	Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant	Complete pathology remission rate	2 week after operation